BIOTECanada

Last updated
BIOTECanada
Formation1987;37 years ago (1987)
Headquarters Ottawa, Ontario
Website https://www.biotech.ca/
Formerly called
Industrial Biotechnology Association of Canada

BIOTECanada, previously the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ontario. [1] It is an industry-funded membership organization composed of over 250 national and international pharmaceutical and gene therapy companies, medical device manufacturers, agricultural science businesses, law firms, academic institutions, research and development networks, advertising agencies, insurance companies and financial services firms. [2] [3]

Contents

BIOTECanada and the University of Western Ontario jointly administer the Gold Leaf Awards, presented annually to individuals and organizations who are deemed to have made significant contributions to Canada's biotechnology sector. [4]

History

The organization was incorporated in 1987 as the Industrial Biotechnology Association of Canada. [5]

Health Canada partnered with BIOTECanada in May 2012 to organize a summit on clinical and regulatory topics associated with biosimilars. [6] The event was held in association with the International Alliance for Biological Standardization, and was observed by representatives from the Patented Medicine Prices Review Board and the Canadian Agency for Drugs and Technologies in Health. Panelists included representatives from academia, regulatory bodies and industry, such as UMass Memorial Health, Janssen Pharmaceuticals, the Robarts Research Institute, Alberta Blue Cross, Mount Sinai Hospital and Sunnybrook Health Sciences Centre. [6]

In 2017, BIOTECanada published a report detailing proposed initiatives to use biotechnology to address issues including population growth, climate change, food security, health, and economic instability. [7] President and CEO Andrew Casey sent a letter in July 2017 to Innovation, Science and Economic Development Canada proposing measures to offset costs of patent filings, and to reduce taxation on intellectual property revenues. [3]

COVID-19

Several representatives of BIOTECanada participated as members and advisors in the COVID-19 Therapeutics Task Force convened by Innovation, Science and Economic Development Canada. [8]

In June 2022, BIOTECanada hosted the Canada Pavilion at the BIO International Convention, an annual biotechnology conference led by the Biotechnology Innovation Organization (BIO). [9]

Organization

Partners

BIOTECanada is partnered with Avantor, Borden Ladner Gervais, Silicon Valley Bank, and Wilson Sonsini Goodrich & Rosati. [10] The organization is a supporting member of BioTalent Canada, a professional network for the biotechnology community. [2] It is also a member of the Biotechnology Innovation Organization (BIO), [11] and a founding institution of Clinical Trials Ontario. [12] It is a participating organization of the Virtual Biosecurity Center, an initiative of the Federation of American Scientists. [13]

Members

BIOTECanada's current membership includes: [14]

Former members include the Agricultural Institute of Canada, BioAlberta, Centre for the Commercialization of Antibodies and Biologics, Ernst & Young, Genzyme, Innovation PEI, International Centre for Infectious Disease, Johnson & Johnson, KPMG, Life Sciences Association of Manitoba, McKesson Corporation, National Research Council Canada, Pan-Provincial Vaccine Enterprise, PricewaterhouseCoopers, Sanofi Pasteur, Shoppers Drug Mart Specialty Health Network, University of Guelph, University of Manitoba and University of Waterloo. [15]

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total.

Pharming, a portmanteau of farming and pharmaceutical, refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming, or biopharming.

A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy. Biologics can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine.

Expenditures by federal and provincial organizations on scientific research and development accounted for about 10% of all such spending in Canada in 2006. These organizations are active in natural and social science research, engineering research, industrial research and medical research.

<span class="mw-page-title-main">California Institute for Quantitative Biosciences</span>

The California Institute for Quantitative Biosciences (QB3) is a nonprofit research and technology commercialization institute affiliated with three University of California campuses in the San Francisco Bay Area: Berkeley, San Francisco, and Santa Cruz. QB3's domain is the quantitative biosciences: areas of biology in which advances are chiefly made by scientists applying techniques from physics, chemistry, engineering, and computer science.

<span class="mw-page-title-main">Bio-1</span>

Bio-1 is a consortium of partners founded in 2007 designed to identify and promote bioscience in the Central New Jersey area. It is the result of a $5 million grant made available by the Workforce Innovation in Regional Economic Development (WIRED) program.

China has seen double-digit growth in its biotechnology industry and has gone from being one of the slowest to one of the fastest nations in the adoption of new biotechnologies. The biotech sector is seen in China and internationally as a core area of national scientific and economic development. The main national biotech body in the country is the China National Center for Biotechnology Development. The CNCBD is an organization established on November 3, 1983, under the Ministry of Science and Technology with the approval of the State Council. CNCBD is the sole national center to coordinate and implement the national S&T program in Biotechnology and Health.

<span class="mw-page-title-main">Ohio bioscience sector</span> Significant economic sector in the state

The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine.

Sanofi Biogenius Canada (SBC), formerly known as the Sanofi BioGENEius Challenge Canada (SBCC), is a national, biotechnology-focused science competition for Canadian high school and CEGEP students.

BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.

Sara Radcliffe is an American medical research advocate and business executive. She is the president and CEO of California Life Sciences Association, a non-profit organization that advocates for the medical research mission of the life sciences sector of California. She is best known for her expertise in the field of applied public health and an advocate for life sciences.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.

<span class="mw-page-title-main">Biotechnology Innovation Organization</span> Biotechnology advocacy association

The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization from a merger of the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC), and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.

<span class="mw-page-title-main">Albert D. Friesen</span>

Albert "Bert" D. Friesen, is a Canadian biotechnologist involved in biotechnology innovation. His biotechnology career began as the first full-time employee of the Winnipeg Rh Institute, where he later became president and CEO, and led the development of WinRho, one of Canada's first successful biotech products.

<span class="mw-page-title-main">Fortress Biotech</span>

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.

DNA Valley is a region in Maryland that serves as a biotechnology hub with a focus on genetic medicine. Roughly traced by Rockville, Frederick, and Baltimore, DNA Valley includes the innovation companies in the Maryland I-270 technology corridor, the various campuses of federal entities such as the FDA and NIH, as well as The University of Maryland, Johns Hopkins University, The Institute for Human Virology, and various laboratories with high biosafety levels such as Fort Detrick. Major DNA valley cities include: Baltimore, Columbia, Germantown, Silver Spring, Rockville, Bethesda, Gaithersburg, College Park, and Frederick. The counties that make up DNA valley are Montgomery County, Frederick County, Howard County, Baltimore County, Anne Arundel County, and Carroll County. According to the Bureau of Economic Analysis, these counties contributed a combined GDP of $310,407,270 in 2021, higher than several nations. Local business leaders like Jeff Galvin expect this figure to increase in step with the growth of the biotechnology sector.

References

  1. ↑ MacDonald, Chris (2004-03-01). "Business Ethics 101 for the Biotech Industry". BioDrugs. 18 (2): 71–77. doi:10.2165/00063030-200418020-00001. ISSN   1179-190X. PMID   15046523. S2CID   26128402.
  2. 1 2 "BIOTECanada". BioTalent Canada. Archived from the original on 2022-09-01. Retrieved 2022-09-01.
  3. 1 2 Casey, Andrew (2017-07-17). "RE: Canada's New Intellectual Property Strategy" (PDF). Innovation, Science and Economic Development Canada . Archived (PDF) from the original on 2022-09-02. Retrieved 2022-09-02.
  4. ↑ "BIOTECanada Gold Leaf Awards". University of Western Ontario . Archived from the original on 2022-09-01. Retrieved 2022-09-01.
  5. ↑ "BIOTECanada". Bioscience Association Manitoba. Archived from the original on 2022-09-01. Retrieved 2022-09-01.
  6. 1 2 Kay, Jonathan; Feagan, Brian G.; Guirguis, Micheal S.; Keystone, Edward C.; Klein, Agnes V.; Lubiniecki, Anthony S.; Mould, Diane R.; Nyarko, Kwasi A.; Ridgway, Anthony A. G.; Trudeau, Maureen E.; Wang, Jian (2012-11-01). "Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012". Biologicals. 40 (6): 517–527. doi: 10.1016/j.biologicals.2012.09.010 . ISSN   1045-1056. PMID   23084808. S2CID   3477502.
  7. ↑ "The Science of Amazing Canada's Biotech Ecosystem". BIOTECanada Ecosystem. 2017. Archived from the original on 2022-09-01. Retrieved 2022-09-02.
  8. ↑ Innovation, Science and Economic Development Canada (2022-03-10). "COVID-19 Therapeutics Task Force". Government of Canada . Archived from the original on 2023-04-27. Retrieved 2023-04-29.
  9. ↑ "Alberta at BIO International 2022". BioAlberta. Archived from the original on 2022-09-01. Retrieved 2022-09-01.
  10. ↑ "About". BIOTECanada. Archived from the original on 2022-08-02. Retrieved 2022-09-01.
  11. ↑ "BIOTECanada". Biotechnology Innovation Organization . Archived from the original on 2024-06-21. Retrieved 2022-09-01.
  12. ↑ "Founding Institutions". Clinical Trials Ontario. Archived from the original on 2024-12-30. Retrieved 2022-10-09.
  13. ↑ "BIOTECanada". Virtual Biosecurity Center. Archived from the original on 2022-09-01. Retrieved 2022-09-01.
  14. ↑ "Member Listings". BIOTECanada. 2021-12-23. Archived from the original on 2022-08-02. Retrieved 2022-09-01.
  15. ↑ "Member Listings". BIOTECanada. Archived from the original on 2016-07-14. Retrieved 2022-09-01.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.